MCID: ABD014
MIFTS: 54

Abdominal Obesity-Metabolic Syndrome 1

Categories: Genetic diseases, Metabolic diseases

Aliases & Classifications for Abdominal Obesity-Metabolic Syndrome 1

MalaCards integrated aliases for Abdominal Obesity-Metabolic Syndrome 1:

Name: Abdominal Obesity-Metabolic Syndrome 1 53 12
Metabolic Syndrome X 53 12 72 28 51 14 69
Metabolic Syndrome 41 59
Abdominal Obesity Metabolic Syndrome 69
Dysmetabolic Syndrome X 12
Aoms1 53

Characteristics:

OMIM:

53
Inheritance:
autosomal dominant


HPO:

31
abdominal obesity-metabolic syndrome 1:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 53 605552
Disease Ontology 12 DOID:14221
ICD10 32 E88.81
ICD9CM 34 277.7
MeSH 41 D024821
NCIt 46 C84442
SNOMED-CT 64 190394009 237602007
MedGen 39 C2930930

Summaries for Abdominal Obesity-Metabolic Syndrome 1

OMIM : 53 A clustering of abdominal obesity, high triglycerides, low levels of high density lipoprotein cholesterol (HDLC), high blood pressure, and elevated fasting glucose levels is sometimes called metabolic syndrome X (Reaven, 1988) or abdominal obesity-metabolic syndrome (Bjorntorp, 1991). The syndrome may affect nearly 1 in 4 U.S. adults and is considered a veritable epidemic (Ford et al., 2002). It is a major risk factor for both diabetes mellitus (see 125853 and Haffner et al., 1992) and cardiovascular disease (Isomaa et al., 2001). The etiology is complex, determined by the interplay of both genetic and environmental factors. The prevalence varies substantially among ethnic groups, with the highest rates in Mexican American women (Park et al., 2003). Other factors influencing the metabolic syndrome include age, smoking, alcohol, diet, and physical inactivity. (605552)

MalaCards based summary : Abdominal Obesity-Metabolic Syndrome 1, also known as metabolic syndrome x, is related to abdominal obesity-metabolic syndrome quantitative trait locus 2 and abdominal obesity-metabolic syndrome 3, and has symptoms including hypertension, abdominal obesity and edema. An important gene associated with Abdominal Obesity-Metabolic Syndrome 1 is MTTP (Microsomal Triglyceride Transfer Protein), and among its related pathways/superpathways are Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) and Common Cytokine Receptor Gamma-Chain Family Signaling Pathways. The drugs Ezetimibe and Simvastatin have been mentioned in the context of this disorder. Affiliated tissues include heart, liver and brain, and related phenotypes are adipose tissue and cardiovascular system

PubMed Health : 59
About metabolic syndrome: Metabolic (met-ah-BOL-ik) syndrome is the name for a group of risk factors that raises your risk for heart disease and other health problems, such as diabetes and stroke.The term "metabolic" refers to the biochemical processes involved in the body's normal functioning. Risk factors are traits, conditions, or habits that increase your chance of developing a disease.In this article, "heart disease" refers to coronary heart disease (CHD). CHD is a condition in which a waxy substance called plaque (plak) builds up inside the coronary (heart) arteries.Plaque hardens and narrows the arteries, reducing blood flow to your heart muscle. This can lead to chest pain, a heart attack, heart damage, or even death.

Wikipedia : 72 Metabolic syndrome, sometimes known by other names, is a clustering of at least three of the five... more...

Related Diseases for Abdominal Obesity-Metabolic Syndrome 1

Diseases in the Abdominal Obesity-Metabolic Syndrome 1 family:

Abdominal Obesity-Metabolic Syndrome 3

Diseases related to Abdominal Obesity-Metabolic Syndrome 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Related Disease Score Top Affiliating Genes
1 abdominal obesity-metabolic syndrome quantitative trait locus 2 31.7 AOMS1 INS LEP SLC2A4
2 abdominal obesity-metabolic syndrome 3 12.1
3 lipodystrophy, familial partial, type 2 10.2 INS LEP
4 pituitary-dependent cushing's disease 10.2 HSD11B1 INS
5 fetal macrosomia 10.1 INS LEP
6 congenital generalized lipodystrophy 10.1 INS LEP
7 alstrom syndrome 10.1 INS LEP
8 intracranial hypertension 10.0 HSD11B1 SERPINE1
9 anovulation 10.0 INS LEP
10 pancreas disease 9.9 INS LEP
11 hyperthyroidism 9.9 GHRL INS LEP
12 familial partial lipodystrophy 9.8 INS LEP PPARG
13 acquired generalized lipodystrophy 9.8 ADIPOQ LEP
14 adrenal gland hyperfunction 9.8 GHRL LEP
15 obesity-hypoventilation syndrome 9.8 ADIPOQ LEP
16 idiopathic recurrent pericarditis 9.8 ADIPOQ LEP
17 multiple symmetrical lipomatosis 9.8 ADIPOQ LEP
18 nontuberculous mycobacterial lung disease 9.8 ADIPOQ LEP
19 coronary artery aneurysm 9.8 ADIPOQ LEP
20 bulimia nervosa 1 9.7 GHRL LEP
21 polycystic ovary syndrome 9.7 GHRL HSD11B1 INS LEP
22 hyperinsulinism 9.6 GHRL INS LEP SERPINE1
23 idiopathic edema 9.6 ADIPOQ INS PPARG
24 nonalcoholic steatohepatitis 9.6 ADIPOQ INS LEP
25 apnea, obstructive sleep 9.6 ADIPOQ INS LEP
26 acanthosis nigricans 9.6 ADIPOQ INS LEP
27 coronary artery anomaly 9.6 ADIPOQ INS SERPINE1
28 inherited metabolic disorder 9.6 ADIPOQ INS LEP
29 eating disorder 9.6 ADIPOQ GHRL LEP
30 bulimia nervosa 2 9.6 ADIPOQ GHRL LEP
31 liver disease 9.5 ADIPOQ INS LEP
32 coronary heart disease 1 9.5 ADIPOQ INS MTTP SERPINE1
33 3-hydroxyacyl-coa dehydrogenase deficiency 9.4 ADIPOQ GHRL INS PPARG
34 sleep apnea 9.4 ADIPOQ GHRL INS LEP
35 pre-eclampsia 9.4 ADIPOQ LEP SERPINE1
36 prader-willi syndrome 9.3 ADIPOQ GHRL INS LEP
37 myocardial infarction 9.3 ADIPOQ GHRL INS SERPINE1
38 atherosclerosis susceptibility 9.3 ADIPOQ INS PPARG SERPINE1
39 arteriosclerosis 9.3 ADIPOQ INS PPARG SERPINE1
40 prediabetes syndrome 9.3 ADIPOQ INS LEP PPARG
41 vascular disease 9.3 ADIPOQ INS PPARG SERPINE1
42 hypertension, essential 9.3 ADIPOQ INS LEP SERPINE1
43 lipodystrophy 9.3 ADIPOQ INS LEP PPARG
44 hyperglycemia 9.2 ADIPOQ INS LEP PPARG
45 endocrine pancreas disease 9.2 ADIPOQ INS LEP SLC2A4
46 gestational diabetes 9.2 ADIPOQ INS LEP SLC2A4
47 fatty liver disease 9.0 ADIPOQ INS LEP MTTP PPARG
48 lutheran suppressor, x-linked 9.0 ADIPOQ HSD11B1 INS LEP SERPINE1
49 morbid obesity 9.0 ADIPOQ GHRL INS LEP PPARG
50 arteries, anomalies of 8.9 ADIPOQ INS LEP PPARG SERPINE1

Graphical network of the top 20 diseases related to Abdominal Obesity-Metabolic Syndrome 1:



Diseases related to Abdominal Obesity-Metabolic Syndrome 1

Symptoms & Phenotypes for Abdominal Obesity-Metabolic Syndrome 1

Symptoms via clinical synopsis from OMIM:

53
Growth Weight:
abdominal obesity

Laboratory Abnormalities:
elevated fasting glucose levels

Cardiovascular Vascular:
hypertension


Clinical features from OMIM:

605552

Human phenotypes related to Abdominal Obesity-Metabolic Syndrome 1:

31
# Description HPO Frequency HPO Source Accession
1 hypertension 31 HP:0000822
2 abdominal obesity 31 HP:0012743

UMLS symptoms related to Abdominal Obesity-Metabolic Syndrome 1:


edema, chest pain, angina pectoris

MGI Mouse Phenotypes related to Abdominal Obesity-Metabolic Syndrome 1:

43 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 adipose tissue MP:0005375 10.1 LEP PPARG SERPINE1 SLC2A4 ADIPOQ GHRL
2 cardiovascular system MP:0005385 10.08 ADIPOQ HSD11B1 INS LEP MTTP PPARG
3 growth/size/body region MP:0005378 10.03 ADIPOQ HSD11B1 INS LEP MTTP PPARG
4 homeostasis/metabolism MP:0005376 10.02 ADIPOQ GHRL HSD11B1 INS LEP MTTP
5 endocrine/exocrine gland MP:0005379 10 ADIPOQ GHRL HSD11B1 INS LEP PPARG
6 hematopoietic system MP:0005397 9.95 ADIPOQ HSD11B1 INS LEP MTTP PPARG
7 immune system MP:0005387 9.87 ADIPOQ HSD11B1 INS LEP PPARG SERPINE1
8 liver/biliary system MP:0005370 9.76 ADIPOQ HSD11B1 INS LEP MTTP PPARG
9 integument MP:0010771 9.73 INS LEP PPARG SERPINE1 ADIPOQ HSD11B1
10 muscle MP:0005369 9.43 ADIPOQ HSD11B1 INS LEP PPARG SLC2A4
11 renal/urinary system MP:0005367 9.02 ADIPOQ INS LEP PPARG SERPINE1

Drugs & Therapeutics for Abdominal Obesity-Metabolic Syndrome 1

PubMedHealth treatment related to Abdominal Obesity-Metabolic Syndrome 1: 59

Healthy lifestyle changes are the first line of treatment for metabolic syndrome. Lifestyle changes include losing weight, being physically active, following a heart healthy diet, and quitting smoking.If lifestyle changes aren't enough, your doctor may prescribe medicines. Medicines are used to treat and control risk factors such as high blood pressure, high triglycerides, low HDL cholesterol, and high blood sugar.Blood-thinning medicines, such as aspirin, also may be used to reduce the risk of blood clots. Excessive blood clotting is a condition that often occurs with metabolic syndrome.

Drugs for Abdominal Obesity-Metabolic Syndrome 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 719)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ezetimibe Approved Phase 4,Phase 3,Not Applicable 163222-33-1 150311
2
Simvastatin Approved Phase 4,Phase 3,Phase 2,Not Applicable 79902-63-9 54454
3
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 657-24-9 4091 14219
4
Ranolazine Approved, Investigational Phase 4 95635-55-5, 142387-99-3 56959
5
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
6
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 1 137862-53-4 60846
7
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
8
Eplerenone Approved Phase 4,Phase 3 107724-20-9 443872 150310
9
Spironolactone Approved Phase 4,Phase 3,Not Applicable 1952-01-7, 52-01-7 5833
10
Hydrocortisone Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 50-23-7 657311 5754
11
Metyrapone Approved, Investigational Phase 4 54-36-4 4174
12
Orlistat Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 96829-58-2 3034010
13
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-18-4 6010
14
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-22-0 6013
15
Amlodipine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 88150-42-9 2162
16
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1 58-93-5 3639
17
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 129722-12-9 60795
18
Losartan Approved Phase 4,Phase 3,Phase 2,Not Applicable 114798-26-4 3961
19
Olmesartan Approved, Investigational Phase 4,Phase 3 144689-24-7, 144689-63-4 158781 130881
20
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 111025-46-8 4829
21
Zinc Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 7440-66-6 32051 23994
22
Cyproterone Acetate Approved, Investigational Phase 4,Not Applicable 427-51-0
23
Ethinyl Estradiol Approved Phase 4,Phase 2,Not Applicable 57-63-6 5991
24
Liraglutide Approved Phase 4,Phase 3 204656-20-2 44147092
25
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
26
Curcumin Approved, Investigational Phase 4,Phase 2,Not Applicable 458-37-7 969516
27
Clozapine Approved Phase 4,Phase 2,Not Applicable 5786-21-0 2818
28
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
29
Haloperidol Approved Phase 4,Not Applicable 52-86-8 3559
30
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 132539-06-1 4585
31
Risperidone Approved, Investigational Phase 4,Phase 3,Not Applicable 106266-06-2 5073
32
Ziprasidone Approved Phase 4,Phase 3,Phase 2,Not Applicable 146939-27-7 60854
33
Irbesartan Approved, Investigational Phase 4,Not Applicable 138402-11-6 3749
34
Rosiglitazone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 122320-73-4 77999
35
Histamine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 51-45-6, 75614-87-8 774
36
Fenofibrate Approved Phase 4,Phase 3,Phase 2,Not Applicable 49562-28-9 3339
37
Allopurinol Approved Phase 4,Phase 2,Not Applicable 315-30-0 2094
38
Magnesium oxide Approved Phase 4,Phase 3,Phase 2 1309-48-4 14792
39
Iron Approved Phase 4,Not Applicable 7439-89-6 23925
40
Ethanol Approved Phase 4,Phase 3,Not Applicable 64-17-5 702
41
Galantamine Approved Phase 4 357-70-0 9651
42
Clopidogrel Approved Phase 4,Not Applicable 120202-66-6, 113665-84-2 60606
43
Ticlopidine Approved Phase 4 55142-85-3 5472
44 Titanium dioxide Approved Phase 4,Phase 3,Phase 2 13463-67-7
45
Pitavastatin Approved Phase 4,Phase 1 147511-69-1, 147526-32-7 5282452 6366718
46
Fluvastatin Approved Phase 4,Phase 3 93957-54-1 1548972
47
Telmisartan Approved, Investigational Phase 4,Phase 3,Phase 2 144701-48-4 65999
48
Cilnidipine Approved, Investigational Phase 4 132203-70-4 5282138
49
Nifedipine Approved Phase 4 21829-25-4 4485
50
Enalapril Approved, Vet_approved Phase 4 75847-73-3 40466924 5362032

Interventional clinical trials:

(show top 50) (show all 1764)

# Name Status NCT ID Phase Drugs
1 Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome. Unknown status NCT00988364 Phase 4 Simvastatin;Vytorin;Placebo;Ezetimibe
2 Effect of Growth Hormone in Metabolic Syndrome Unknown status NCT00307411 Phase 4 Growth hormone
3 Effect of Vitamin D on Metabolic Parameters in Patients With the Metabolic Syndrome Unknown status NCT01237769 Phase 4 Vitamin D3
4 Trial of Supplementation With Aged Garlic Extract to Improve Endothelial Function in Patients With Metabolic Syndrome Unknown status NCT01168700 Phase 4 aged garlic extract;Placebo
5 Metformin in Postmenopausal Women With Metabolic Syndrome Unknown status NCT01342744 Phase 4 Metformin;Placebo
6 Ranolazine, Ethnicity and the Metabolic Syndrome Unknown status NCT01304095 Phase 4 Ranolazine
7 The ACT-OUT Trial: ACTivity OUTcomes Based on High Carbohydrate or High Fat Diet in Metabolic Syndrome Unknown status NCT01357382 Phase 4
8 Continuous Positive Airway Pressure in Sleep Apnea Syndrome: Effects on Metabolic Syndrome and Cardiac Damage Unknown status NCT00517777 Phase 4
9 Kagoshima Collaborate Trial in Metabolic Syndrome (KACT Study) Unknown status NCT00790946 Phase 4 Valsartan
10 Rajavithi Health Promotion Project (Population Base Cohort) Unknown status NCT00368095 Phase 4
11 Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness Unknown status NCT00573950 Phase 4 cilostazol;Placebo
12 Diurnal Variation of Plasminogen Activator Inhibitor-1 Unknown status NCT00515021 Phase 4 Eplerenone (Morning vs. evening drug regimen)
13 Cortisol and Nutritional Sympathetic Responsiveness Unknown status NCT01620684 Phase 4 metyrapone;placebo
14 Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients Unknown status NCT00871845 Phase 4 Orlistat
15 Efficacy and Safety of Lobeglitazone Versus Sitagliptin Unknown status NCT02480465 Phase 4 Lobelitazone 0.5mg;Sitagliptin 100mg
16 Odense Androgen Study - The Effect of Testim and Training in Hypogonadal Men Unknown status NCT00700024 Phase 4 Testim;placebo
17 Regression of Fatty Heart by Valsartan Therapy Unknown status NCT00745953 Phase 4 Valsartan;Hydrochlorothiazide
18 The Monitor of Serum Prolactin Level in a 3 Months Aripiprazole Trial Unknown status NCT00468533 Phase 4 Aripiprazole
19 Changes in Endothelial Function and Biomarkers in African Americans (AA) With Metabolic Syndrome Unknown status NCT01271374 Phase 4 amlodipine and olmesartan;losartan and HCTZ
20 Evaluation of the Effects of Laying Early a Gastric Band on the Prevention of Morbid Obesity Randomized Checked Against Standard Management of Obesity in This Population. Unknown status NCT01700738 Phase 4
21 Treatment of Coronary Atherosclerosis by Insulin Sensitizers in Insulin-Resistant Patients Unknown status NCT00155350 Phase 4 pioglitazone
22 Therapeutic Monitoring of Metformin in Women With Polycystic Ovary Syndrome Unknown status NCT01366391 Phase 4 Metformin
23 PCOS, Therapy and Markers of Cardiovascular Risk Unknown status NCT01798875 Phase 4 oral metformin;oral contraceptive
24 A Trial to Study the Effect of Long Term Vitamin D Supplementation on Insulin Sensitivity Unknown status NCT01052181 Phase 4 Cholecalciferol;placebo
25 Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
26 Korean AMADEUS Study Unknown status NCT01239849 Phase 4 Atorvastatin, 10mg, 20mg, 40mg
27 Vitamin D and Glucose Metabolism in Pediatrics Unknown status NCT01386736 Phase 4 Vitamin D drops;Placebo drops
28 Study of the Effect of Moxonidine and Diet on Sympathetic Functions in Young Adults With Obesity Unknown status NCT01180231 Phase 4 Moxonidine (Physiotens)
29 Clinical Study to Evaluate the Efficacy of Anakinra in Patients With Rheumatoid Arthritis and Diabetes Unknown status NCT02236481 Phase 4 Anakinra;TNF alpha inhibitors
30 Curcumin for Type 2 Diabetic Patients Unknown status NCT01052597 Phase 4 curcumin
31 Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics Unknown status NCT00845936 Phase 4 Metformin
32 Randomized Evaluation of the Effectiveness of Clozapine and Aripiprazole Versus Clozapine and Haloperidol in the Treatment of Schizophrenia Unknown status NCT00395915 Phase 4 aripiprazole
33 The Effect of Metformin on Obesity and Metabolic Disturbance in Patients Taking Clozapine Unknown status NCT01654640 Phase 4 Metformin;Placebo (for metformin)
34 Galantamine Effects in Patients With Metabolic Syndrome Completed NCT02283242 Phase 4 Galantamine;Placebo (for galantamine)
35 PROCLAIM: Study Examining Effects of Clopidogrel Compared to Placebo on Inflammation in Subjects With Metabolic Syndrome Completed NCT00296803 Phase 4 clopidogrel
36 An Observational Study On Metabolic Syndrome Parameters In Schizophrenia Patients Treated With Atypical Antipsychotics Completed NCT00448630 Phase 4
37 Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion Completed NCT02113241 Phase 4 Dapagliflozin;Placebo
38 ROMEO (Rosuvastatin in Metabolic syndrOme) Completed NCT00395486 Phase 4 Rosuvastatin;Atorvastatin
39 Mesoglycan, Vascular Reactivity and Metabolic Syndrome Completed NCT02254850 Phase 4 Mesoglycan;Mesoglycan;Placebo;Placebo
40 Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible diabeTes (ATTEMPT) Completed NCT00416741 Phase 4
41 Safety and Efficacy Study of Pitavastatin in Patient With a Metabolic Syndrome Completed NCT00640276 Phase 4 pitavastatin
42 The Effect of Fluvastatin XL® Treatment in Patients With Metabolic Syndrome Completed NCT00664742 Phase 4 Fluvastatin XL®
43 Other Effects of Fluvastatin Are Investigated in Patients With Metabolic Syndrome Completed NCT00138528 Phase 4 Fluvastatin
44 Cardiovascular Risk Evaluation in Clinical Practice in Metabolic Syndrome Patients Completed NCT00171548 Phase 4
45 Effect of Crestor (Rosuvastatin) on Lipid Levels in Patients With Metabolic Syndrome Completed NCT00815659 Phase 4 rosuvastatin
46 Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome Completed NCT00110422 Phase 4 Irbesartan;Hydrochlorothiazide
47 The Effects of Peroxisome Proliferators Activated Receptor-Gamma (PPAR-γ) Agonists on Certain Biochemical and Inflammatory Markers in Metabolic Syndrome Completed NCT00926341 Phase 4 Pioglitazone;Telmisartan
48 Korean Rosuvastatin Effectiveness Study in Nondiabetic Metabolic Syndrome Completed NCT00335699 Phase 4 Rosuvastatin
49 Effect of Magnesium Administration in Subjects With Family History of Diabetes or Metabolic Syndrome Completed NCT01181830 Phase 4 magnesium pidolate;placebo
50 The Effects of Cilnidipine on Metabolic Syndrome Improvement Completed NCT00325936 Phase 4 Cilnidipine

Search NIH Clinical Center for Abdominal Obesity-Metabolic Syndrome 1

Cochrane evidence based reviews: metabolic syndrome

Genetic Tests for Abdominal Obesity-Metabolic Syndrome 1

Genetic tests related to Abdominal Obesity-Metabolic Syndrome 1:

# Genetic test Affiliating Genes
1 Metabolic Syndrome X 28 MTTP

Anatomical Context for Abdominal Obesity-Metabolic Syndrome 1

MalaCards organs/tissues related to Abdominal Obesity-Metabolic Syndrome 1:

38
Heart, Liver, Brain

Publications for Abdominal Obesity-Metabolic Syndrome 1

Articles related to Abdominal Obesity-Metabolic Syndrome 1:

(show top 50) (show all 60)
# Title Authors Year
1
Circulating adipokines and insulin resistance in subjects with combined cardiac and metabolic syndrome X. ( 26413164 )
2015
2
The question of metabolic syndrome X. ( 26631307 )
2015
3
Glycyrrhizin ameliorates insulin resistance, hyperglycemia, dyslipidemia and oxidative stress in fructose-induced metabolic syndrome-X in rat model. ( 23923606 )
2013
4
Anaesthetic considerations in metabolic syndrome X. ( 20532086 )
2010
5
Central retinal artery occlusion in a patient with metabolic syndrome x. ( 22737328 )
2010
6
Beneficial effects of modified egg* on oxidative stress in F1- generation of metabolic syndrome-X induced Wistar rat. ( 19374165 )
2009
7
Cardiac syndrome X versus metabolic syndrome X. ( 17010457 )
2007
8
[The metabolic syndrome X or insulin resistance syndrome]. ( 17304724 )
2007
9
Is metabolic syndrome X a disorder of the brain with the initiation of low-grade systemic inflammatory events during the perinatal period? ( 17475465 )
2007
10
Aberrant expression of perilipins and 11-beta-HSD-1 as molecular signatures of metabolic syndrome X in south east Asians. ( 16941796 )
2006
11
Long term excessive Zn-supplementation promotes metabolic syndrome-X in Wistar rats fed sucrose and fat rich semisynthetic diet. ( 16999025 )
2006
12
Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X. ( 16416266 )
2006
13
A role for sphingolipids in producing the common features of type 2 diabetes, metabolic syndrome X, and Cushing's syndrome. ( 15734832 )
2005
14
Pathophysiology of metabolic syndrome X and its links to the perinatal period. ( 15925303 )
2005
15
Therapeutic actions of an insulin receptor activator and a novel peroxisome proliferator-activated receptor gamma agonist in the spontaneously hypertensive obese rat model of metabolic syndrome X. ( 15833894 )
2005
16
Low-flow vascular remodeling in the metabolic syndrome X. ( 14644764 )
2004
17
Metabolic syndrome X: an inflammatory condition? ( 14972097 )
2004
18
Swiss Medical Weekly Young Investigator's Award 2003: Clustering of cardiovascular risk factors mimicking the human metabolic syndrome X in eNOS null mice. ( 15243846 )
2004
19
HIV, metabolic syndrome X, inflammation, oxidative stress, and coronary heart disease risk : role of protease inhibitor exposure. ( 15470277 )
2004
20
Role of magnesium in insulin action, diabetes and cardio-metabolic syndrome X. ( 12537988 )
2003
21
The role of I(1)-imidazoline receptors and alpha(2)-adrenergic receptors in the modulation of glucose and lipid metabolism in the SHROB model of metabolic syndrome X. ( 15028595 )
2003
22
Metabolic syndrome X is common in Indians: but, why and how? ( 14719590 )
2003
23
Pathobiology of metabolic syndrome X in obese and non-obese South Asian Indians: further discussion and some suggestions. ( 12781862 )
2003
24
Are metabolic risk factors one unified syndrome? Modeling the structure of the metabolic syndrome X. ( 12697574 )
2003
25
Longitudinal changes in risk variables underlying metabolic Syndrome X from childhood to young adulthood in female subjects with a history of early menarche: the Bogalusa Heart Study. ( 14574352 )
2003
26
Clustering of cardiovascular risk factors mimicking the human metabolic syndrome X in eNOS null mice. ( 12947532 )
2003
27
The role of I(1)-imidazoline and alpha(2)-adrenergic receptors in the modulation of glucose metabolism in the spontaneously hypertensive obese rat model of metabolic syndrome X. ( 12756274 )
2003
28
The inflammatory response is an integral part of the stress response: Implications for atherosclerosis, insulin resistance, type II diabetes and metabolic syndrome X. ( 12946657 )
2003
29
Metabolic syndrome X--high risk factor for acute myocardial infarction and its complications. ( 12137304 )
2002
30
Molecular mechanism of vascular disease in metabolic syndrome X. ( 11872360 )
2002
31
The metabolic syndrome X and peripheral cortisol synthesis. ( 12397528 )
2002
32
Metabolic syndrome X is common in South Asians, but why and how? ( 12297221 )
2002
33
Rosiglitazone improves insulin resistance, lipid profile and promotes adiposity in a genetic model of metabolic syndrome X. ( 12512799 )
2002
34
Plasma glucagon and free fatty acid responses to a glucose load in the obese spontaneous hypertensive rat (SHROB) model of metabolic syndrome X. ( 11856814 )
2002
35
Is metabolic syndrome X an inflammatory condition? ( 12486208 )
2002
36
Obesity, metabolic syndrome X, and inflammation. ( 11985951 )
2002
37
Metabolic syndrome X: a comprehensive review of the pathophysiology and recommended therapy. ( 11958275 )
2001
38
Steroid metabolism in metabolic syndrome X. ( 11469814 )
2001
39
Hypothalamic-pituitary-adrenal axis function and the metabolic syndrome X of obesity. ( 15573024 )
2001
40
Unravelling metabolic syndrome X. ( 11427370 )
2001
41
Metabolic syndrome X and fibrinolytic disturbances. ( 10870268 )
2000
42
Insulin resistance: the metabolic syndrome X ( 10713753 )
2000
43
Haemodynamic and metabolic effects of rilmenidine in hypertensive patients with metabolic syndrome X. A double-blind parallel study versus amlodipine. ( 11057441 )
2000
44
Metabolic syndrome X: a review. ( 10863169 )
2000
45
The metabolic syndrome X. ( 10842649 )
1999
46
Liver pathology and the metabolic syndrome X in severe obesity. ( 10323371 )
1999
47
Enhanced activity of sodium-lithium countertransport in patients with cardiac syndrome X: a potential link between cardiac and metabolic syndrome X. ( 10483984 )
1999
48
Correlation of fasting serum C-peptide and insulin with markers of metabolic syndrome-X in a homogenous Chinese population with normal glucose tolerance. ( 10189006 )
1999
49
Hypothalamic origin of the metabolic syndrome X. ( 10842670 )
1999
50
Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. ( 10842660 )
1999

Variations for Abdominal Obesity-Metabolic Syndrome 1

ClinVar genetic disease variations for Abdominal Obesity-Metabolic Syndrome 1:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 GHRL NM_001134944.1(GHRL): c.178C> A (p.Leu60Met) single nucleotide variant Pathogenic,risk factor rs696217 GRCh37 Chromosome 3, 10331457: 10331457

Copy number variations for Abdominal Obesity-Metabolic Syndrome 1 from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 267520 mtDNA 1 16569 Copy number Metabolic syndrome

Expression for Abdominal Obesity-Metabolic Syndrome 1

Search GEO for disease gene expression data for Abdominal Obesity-Metabolic Syndrome 1.

Pathways for Abdominal Obesity-Metabolic Syndrome 1

Pathways related to Abdominal Obesity-Metabolic Syndrome 1 according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.63 ADIPOQ LEP PPARG SLC2A4
2
Show member pathways
12.49 ADIPOQ INS LEP SLC2A4
3 12.22 ADIPOQ INS PPARG SLC2A4
4
Show member pathways
12.14 ADIPOQ INS LEP PPARG SLC2A4
5
Show member pathways
11.97 GHRL INS LEP
6
Show member pathways
11.93 INS LEP SLC2A4
7
Show member pathways
11.85 ADIPOQ INS PPARG
9 11.64 ADIPOQ INS LEP PPARG SLC2A4
10
Show member pathways
11.62 ADIPOQ INS SLC2A4
11 11.42 ADIPOQ LEP SLC2A4
12 11.3 LEP SLC2A4
13 11.27 INS LEP
14 11.22 ADIPOQ INS LEP PPARG SERPINE1 SLC2A4
15 11.21 INS SLC2A4
16 11.01 INS SLC2A4
17 10.94 ADIPOQ LEP PPARG
18 10.8 ADIPOQ LEP PPARG SLC2A4
19 10.68 INS SLC2A4

GO Terms for Abdominal Obesity-Metabolic Syndrome 1

Cellular components related to Abdominal Obesity-Metabolic Syndrome 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum lumen GO:0005788 8.8 GHRL INS MTTP

Biological processes related to Abdominal Obesity-Metabolic Syndrome 1 according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 lipid metabolic process GO:0006629 9.89 HSD11B1 LEP MTTP PPARG
2 response to ethanol GO:0045471 9.65 ADIPOQ LEP SLC2A4
3 regulation of receptor activity GO:0010469 9.65 ADIPOQ GHRL INS LEP SERPINE1
4 fatty acid beta-oxidation GO:0006635 9.64 ADIPOQ LEP
5 response to activity GO:0014823 9.63 ADIPOQ LEP
6 placenta development GO:0001890 9.63 LEP PPARG
7 negative regulation of smooth muscle cell proliferation GO:0048662 9.62 ADIPOQ PPARG
8 positive regulation of glucose import GO:0046326 9.62 ADIPOQ INS
9 brown fat cell differentiation GO:0050873 9.61 ADIPOQ SLC2A4
10 positive regulation of interleukin-8 production GO:0032757 9.61 ADIPOQ SERPINE1
11 cellular response to insulin stimulus GO:0032869 9.61 ADIPOQ PPARG SLC2A4
12 glucose transport GO:0015758 9.6 INS SLC2A4
13 negative regulation of vascular smooth muscle cell proliferation GO:1904706 9.58 ADIPOQ PPARG
14 lipoprotein transport GO:0042953 9.58 MTTP PPARG
15 response to nutrient GO:0007584 9.58 ADIPOQ LEP PPARG
16 positive regulation of cellular protein metabolic process GO:0032270 9.57 ADIPOQ INS
17 fatty acid oxidation GO:0019395 9.56 ADIPOQ PPARG
18 regulation of fat cell differentiation GO:0045598 9.55 LEP PPARG
19 negative regulation of smooth muscle cell migration GO:0014912 9.54 ADIPOQ SERPINE1
20 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.52 ADIPOQ PPARG
21 negative regulation of gluconeogenesis GO:0045721 9.51 ADIPOQ INS
22 response to nutrient levels GO:0031667 9.5 ADIPOQ GHRL LEP
23 positive regulation of insulin receptor signaling pathway GO:0046628 9.49 INS LEP
24 adult feeding behavior GO:0008343 9.46 GHRL LEP
25 circadian rhythm GO:0007623 9.46 ADIPOQ LEP MTTP SERPINE1
26 negative regulation of acute inflammatory response GO:0002674 9.37 INS PPARG
27 glucose metabolic process GO:0006006 9.26 ADIPOQ GHRL INS LEP
28 glucose homeostasis GO:0042593 9.02 ADIPOQ INS LEP PPARG SLC2A4

Molecular functions related to Abdominal Obesity-Metabolic Syndrome 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.92 ADIPOQ GHRL INS LEP

Sources for Abdominal Obesity-Metabolic Syndrome 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....